Analytical Pharmacology Core Facility Shared Resource ABSTRACT The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research between basic scientists and clinicians by providing comprehensive analytical and consultative services in a GLP-capable environment. The APCF assists with the design and implementation of pharmacokinetic, pharmacodynamic, and biomarker correlative studies for clinical and preclinical investigations of small molecules and biologic agents (e.g., antibodies, antisense oligonucleotides, vaccines, and cellular therapeutics). Primary services provided are: 1) quantitative assay development and sample analysis (LC-MS/MS, ICP-MS, GC/MS, HPLC, Luminex, ELISA, qPCR) of drugs, biomarkers, and related compounds; and 2) study design and expert analysis of pharmacokinetic and biomarker data. All major analytical equipment is consolidated into a contiguous suite of rooms in the Shapiro building. The most heavily utilized major equipment within the core are the LC-MS/MS instruments and the FLEXMAP 3D multiplex immunoassay platform. Mass spectrometry instrumentation includes a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, an AB Sciex QTRAP 5500, an Agilent 6410, and a recently acquired Waters Xevo-TQXS. All systems provide state-of-the-art selectivity and sensitivity for detecting and quantifying analytes in complex biological matrices and are interfaced with HPLC front-end components. Additional key core equipment include an Agilent 8800 inductively-coupled plasma triple quadrupole mass spectrometer (ICP-MS) for determination of metals and metal-containing compounds and four complete HPLC systems. For analysis of biological agents, the Core has a FLEXMAP 3D Bioplex instrument for multiplex immunoassays, a Bio-Rad QX200 Droplet Digital PCR for absolute quantitation of gene expression, a FLUOstar OPTIMA multi-label plate reader for a wide range of high-throughput ELISA applications, and a Guava PCA-96 analytical cell analyzer. The core is directed by Dr. Timothy Synold, a Professor in the Department of Cancer Biology, with oversight by an interdisciplinary faculty Advisory Committee. Dr. Synold actively participates in most of the early drug development efforts within the Divisions of Hematology and Medical Oncology, which is reflected in the heavy usage by members of the DCT and HM Programs. User feedback is provided annually through user surveys. Since the last competitive renewal, the APCF contributed to 44 publications by CC members. Over the past five years, the APCF was used by a total of 74 unique investigators, including 56 CC members from all five Programs. Of the 56 CC members, 46 (82%) had peer-reviewed funding. During this period, 147 unique analytical methods were developed or re-initiated and 24,502 samples were analyzed. In addition, 4,632 clinical specimens were processed and 75 separate cancer clinical trials were supported by the core.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512

Showing the most recent 10 out of 1396 publications